Suchergebnisse

Echocardiography has become an indispensable tool for the study of heart performance, improving the monitoring of individuals with cardiac diseases. Diverse genetic factors associated with echocardiographic measures have been previously reported. The impact of several apoptotic genes in heart development identified in experimental models prompted us to assess their potential association with human cardiac function. This study aimed at investigating the possible association of variants of apoptotic genes with echocardiographic traits and to identify new genetic markers associated with cardiac function. Genome wide data from different studies were obtained from public repositories. After quality control and imputation, a meta-analysis of individual association study results was performed. Our results confirmed the role of caspases and other apoptosis related genes with cardiac phenotypes. Moreover, enrichment analysis showed an over-representation of genes, including some apoptotic regulators, associated with Alzheimer's disease. We further explored this unexpected observation which was confirmed by genetic correlation analyses. Our findings show the association of apoptotic gene variants with echocardiographic indicators of heart function and reveal a novel potential genetic link between echocardiographic measures in healthy populations and cognitive decline later on in life. These findings may have important implications for preventative strategies combating Alzheimer's disease. ; General. Data collection and sharing for this project was partially funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. For the Alzheimer's Disease Neuroimaging Initiative: Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp19content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. The AddNeuroMed data are from a public-private partnership supported by EFPIA companies and SMEs as part of InnoMed (Innovative Medicines in Europe), an Integrated Project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5. Clinical leads responsible for data collection are Iwona Kłoszewska (Lodz), Simon Lovestone (London), Patrizia Mecocci (Perugia), Hilkka Soininen (Kuopio), Magda Tsolaki (Thessaloniki), and Bruno Vellas (Toulouse), imaging leads are Andy Simmons (London), Lars-Olad Wahlund (Stockholm) and Christian Spenger (Zurich) and bioinformatics leads are Richard Dobson (London) and Stephen Newhouse (London). This dataset was downloaded from Synapse (https://doi.org/10.7303/syn2790911). Funding support for the Alzheimer's Disease Genetics Consortium (ADGC) was provided through the NIA Division of Neuroscience (U01-AG032984). This study was downloaded from NIH dbGaP repository (phs000372.v1). The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (N01-HC95095 & N01-HC48047), University of Minnesota (N01-HC48048), Northwestern University (N01-HC48049), and Kaiser Foundation Research Institute (N01-HC48050). This manuscript was not approved by CARDIA. The opinions and conclusions contained in this publication are solely those of the authors, and are not endorsed by CARDIA or the NHLBI and should not be assumed to reflect the opinions or conclusions of either. Genotyping for the CARDIA GENEVA cohort was supported by grant U01 HG004729 from the National Human Genome Research Institute. This study was downloaded from NIH dbGaP repository (phs000285.v3.p2). The Cardiovascular Heart Study (CHS) was supported by contracts HHSN268201200036C, HHSN268200800007C, N01-HC85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and N01-HC-85239; grant numbers U01 HL080295 and U01 HL130014 from the National Heart, Lung, and Blood Institute, and R01 AG-023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at https://chs-nhlbi.org/pi. This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS or the NHLBI. Support for the genotyping through the CARe Study was provided by NHLBI Contract N01-HC-65226. This study was downloaded from NIH dbGaP repository (phs000287.v5.p1). The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195 and HHSN268201500001I). This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI. "Funding for SHARe Affymetrix genotyping was provided by NHLBI Contract N02-HL64278. SHARe Illumina genotyping was provided under an agreement between Illumina and Boston University. Funding for Affymetrix genotyping of the FHS Omni cohorts was provided by Intramural NHLBI funds from Andrew D. Johnson and Christopher J. O'Donnell. This dataset was obtained from the NIH dbGaP repository (phs000007.v29.p10). The genotypic and associated phenotypic data used in the study, "Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimer's Disease (GenADA)" were provided by the GlaxoSmithKline, R&D Limited. The datasets used for analyses described in this manuscript were obtained from NIH dbGaP repository (phs000219.v1.p1). The Mayo Clinic Alzheimer's Disease Genetic Studies, led by Dr. Nilüfer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. This dataset was downloaded from Synapse (https://doi.org/10.7303/syn5550404). The MESA study was supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from NCATS. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. This dataset was obtained from the NIH dbGaP repository (phs000209.v6.p2). The Neocodex-Murcia study was funded by the Fundación Alzheimur (Murcia), the Ministerio de Educación y Ciencia (Gobierno de España), Corporación Tecnológica de Andalucía and Agencia IDEA (Consejería de Innovación, Junta de Andalucía). The Diabetes Research Laboratory, Biomedical Research Foundation. University Hospital Clínico San Carlos has been supported by CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); CIBERDEM is an ISCIII Project. The ROS/MAP study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. This dataset was downloaded from Synapse (https://doi.org/10.7303/syn3219045). The TGEN study was supported by Kronos Life Sciences Laboratories, the National Institute on Aging (Arizona Alzheimer's Disease Center P30 AG19610, RO1 AG023193, Mayo Clinic Alzheimer's Disease Center P50 AG16574, and Intramural Research Program), the National Alzheimer's Coordinating Center (U01 AG016976), and the state of Arizona. TGEN investigators provided free access to genotype data to other researchers via Coriell Biorepositories (http://www.coriell.org). The results published here are in part based on data obtained from the AMP-AD Knowledge Portal accessed at https://doi.org/10.7303/syn2580853. D.S. research is supported by Grant 20153810 from Fundació La Marató de TV3 and Grant SAF2013-44942-R from the Ministerio de Economía y Competitividad (MINECO) and, with J.X.C., Grant 2009SGR-346 from the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) from the Government of Catalonia. A.B. has a predoctoral contract from Fundació La Marató de TV3. A.R. research is also supported by grants PI13/02434 and PI16/01861. Acción Estratégica en Salud, integrated in the Spanish National R&D&I Plan and financed by ISCIII (Instituto de Salud Carlos III)-Subdirección General de Evaluación and the European Regional Development Fund (ERDF – "A way to make Europe"), by Fundación banca "La Caixa" and Grifols SA (GR@ACE project). This work was also partly supported by the ADAPTED consortium, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115975. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations.

An appropriate response and adaptation to hyperosmolarity, i.e., an external osmolarity that is higher than the physiological range, can be a matter of life or death for all cells. It is especially important for free-living organisms such as the yeast Saccharomyces cerevisiae. When exposed to hyperosmotic stress, the yeast initiates a complex adaptive program that includes temporary arrest of cell-cycle progression, adjustment of transcription and translation patterns, and the synthesis and retention of the compatible osmolyte glycerol. These adaptive responses are mostly governed by the high osmolarity glycerol (HOG) pathway, which is composed of membrane-associated osmosensors, an intracellular signaling pathway whose core is the Hog1 MAP kinase (MAPK) cascade, and cytoplasmic and nuclear effector functions. The entire pathway is conserved in diverse fungal species, while the Hog1 MAPK cascade is conserved even in higher eukaryotes including humans. This conservation is illustrated by the fact that the mammalian stress-responsive p38 MAPK can rescue the osmosensitivity of hog1Δ mutations in response to hyperosmotic challenge. As the HOG pathway is one of the best-understood eukaryotic signal transduction pathways, it is useful not only as a model for analysis of osmostress responses, but also as a model for mathematical analysis of signal transduction pathways. In this review, we have summarized the current understanding of both the upstream signaling mechanism and the downstream adaptive responses to hyperosmotic stress in yeast. ; The laboratory of H.S. is supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The laboratory of F.P. is supported by grants from the Ministerio de Economia y Competitividad (Spanish Government), the Consolider Ingenio 2010 Programme, and a FP7 UNICELLSYS grant. F.P. is also supported by the Fundación Marcelino Botín and by the Acadèmia program from Institució Catalana de Recerca i Estudis Avançats (Generalitat de Catalunya).

Esta tesis tiene como objetivo investigar los efectos del etanol y metales pesados (cadmio y mercurio) en los patrones diarios de dos especies acuáticas clave: pez cebra (Darío rerio) y anfípodo gammarus (G. aequicauda y G. chevreuxi). La investigación se realizó en dos niveles organizativos: comportamental y molecular. Con este fin, hemos establecido cuatro objetivos específicos: 1. Investigar los efectos al etanol en el pez cebra en función en su ritmo circadiano. 2. Determinar la existencia de un ritmo diario de la toxicidad del cadmio en el pez cebra. 3. Caracterizar en Gammarus chevreuxi los efectos en la actividad locomotora debido a sedimentos contaminados con mercurio. 4. Evaluar la calidad ambiental de los sedimentos de la cuenca sur del Mar Menor influenciados por históricas actividades mineras. Por lo tanto, estos nuevos datos tiene la intención de señalar la importancia de aplicar un enfoque multidisciplinario para estudios toxicológicos, así como elevar la importancia de la elección del momento adecuado para realizar el ensayo de toxicidad Metodología Los experimentos llevados a cabo en la presente investigación siguieron la legislación española sobre protección de animales y prácticas de laboratorio y fue aprobado tanto por el Comité Nacional de Protección de los Animales y el Comité de Bioética de la Universidad de Murcia - Los muestreo de crustáceos se realizaron en las zonas próximas a la costa mediante el uso de redes de 5 µ de luz de maya. Y su trasporte con aireación y refrigeración . Los muestreos de pez cebra se realizaron en las cámaras del departamento de Fisiología animal. - El etanol se adquirió a través de distribuidores comerciales y los sedimentos tóxicos directamente de las zonas de estudio mediante muestreos con barca. La extracción de los sedimentos se realizó utilizando cores y draga. Se almacenaran en refrigeradores a una temperatura de 4ºC. - Los test de mortalidad y comportamiento se realizaran en cámaras herméticas donde se permite el control de las condiciones de fotoperiodo y temperatura. - Las condiciones del agua antes y después de las exposiciones se medió con electrodos de pH y Oxígeno. - Lo análisis de la actividad ante exposiciones subletales se realizaron en las mismas cámaras y mediante la utilización de equipos de filmación sensibles a las luces infrarrojas, permitiendo así mantener las condiciones de oscuridad en los experimento que sea necesarios. - Determinación de metales pesados en tejidos, utilizamos La Espectroscopia de Emisión en Plasma Acoplado Inductivamente (ICP-AES) con Potencia RF: 1200W, Velocidad de bomba: 30r.p.m., Flujo de gas aux.:0.5l/min, Flujo de gas de nebulización: 0.5 l/min, Flujo de gas de refrigeración: 14 l/min, Flujo de gas de purga: Normal. - Para el estudio de expresión de diferentes genes realizamos la técnica de PCR cuantitativa utilizando SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) y un aparato ABI Prism 7500 (Applied Biosystems, Foster City, CA). Conclusiones 1. La exposición de pez cebra mediante baño a etanol a diferentes horas del día muestra un ritmo de toxicidad que refleja una mayor tasa de mortalidad en larvas durante el día comparado con los efectos durante la noche. Así mismo en adultos de pez cebra se observan efectos en su actividad natatoria y posición en la columna de agua siendo significativamente más severos durante la fase de luz. 2. La exposición de pez cebra mediante baño a cadmio durante diferentes horas del día reflejó un incremento de la mortalidad y acumulación del cadmio en tejidos durante la mitad de la fase de luz, así como una mayor reducción de la actividad locomotora cuando el pez es expuesto a concentraciones subletales, además la expresión de mt1 muestra un pico antes al final de la fase de luz. Todos estos resultados indican que el pez cebra es más vulnerable al cadmio durante la fase de luz que en la fase de oscuridad. 3. La exposición de Gammarus chevreuxi mediante sedimentos contaminados con mercurio mostró un efecto deletéreo en la actividad natatoria incluso en concentraciones consideradas no letales. Dichos efectos fueron más acusados durante el la fase de luz, que corresponde con la más activa del animal. 4. Nuestros resultados sugieren que la actividad locomotora y el número de surfacings se presentan cono una señal temprana de la interacción de los factores co-estresantes temperatura y sedimentos contaminados. Los parámetros comportamentales estudiados en Gammarus. aequicauda y Gammarus. chevreuxi tienen una conexión clara con la supervivencia de los organismos y pueden tener una relevancia ecológica. This thesis aims at investigating the effects of Ethanol and heavy metals (cadmium and mercury) on the daily patterns of two key aquatic species: zebrafish (Dario rerio) and amphipod gammarus (G. aequicauda and G. chevreuxi). The research was conducted in two organizative levels: Physiology behavior and molecular. With this purpose we have established four particular objectives: 1. To investigate time-dependent effects of ethanol exposure in zebrafish. 2. To determine the existence of a daily rhythm of cadmium toxicity in zebrafish. 3. To characterise the effects of locomotor activity to mercury-contaminated sediments in Gammarus chevreuxi. 4. To evaluate the environmental quality of the soft-bottoms from the southern basin of the Mar Menor lagoon influenced by historical mining activities. Hence, this new data intends to point out the importance of applying a multidisciplinary approach to toxicology studies, and also raise the importance of the time experimental setting of toxicity test. Methodology The experiments performed in the present research followed Spanish legislation on Animal Welfare and Laboratory Practices and was approved by both the National Committee on Animal Welfare and the Bioethics Committee of the University of Murcia. - The sampling of gammarids were conducted in the nearshore areas by using mesh of 5 μ. Their transportation was with aeration and cooling. The zebrafish samplings were performed in Animal Physiology's chambers of the department. - Ethanol was purchased by authorized distributors, and toxic sediments were extracted directly from the study areas by boat sampling. Sediments extraction was with cores and dredge. They were stored in the refrigerator at 4 ° C. - The test of mortality and behavior was conducted in chambers where control of the photoperiod and temperature conditions allowed. - Water conditions before and after exposure was measured with pH electrodes and oxygen. - The analysis of activity at sublethal exposures were conducted in the same chamber and using equipment sensitive to infrared light filming, thereby maintaining the conditions of darkness in the experiment is necessary. - Determination of heavy metals in tissues, we used emission spectroscopy Inductively Coupled Plasma (ICP-AES) RF Power: 1200W, pump speed: 30r.pm, aux gas flow: 0.5l / min gas flow. Misting: 0.5 l / min, the cooling gas flow: 14 l / min, purge gas flow: Normal. - Real-time PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and an ABI Prism 7500 apparatus (Applied Biosystems, Foster City, CA). Conclusions 1. Exposure of zebrafish using ethanol bath at different times of day shows a rate of toxicity reflecting a higher rate of mortality in larvae during the day compared to the effects overnight. Also effects in adult zebrafish are observed in their swim and activity position in the water column to be significantly more severe during the light phase. 2. Exposure zebrafish using cadmium bath during different times of day reflected an increase in mortality and cadmium accumulation in tissues during half of the light phase and a further reduction of locomotor activity when the fish is exposed to sublethal concentrations. Expression of mt1 shows a peak before the end of the light phase. All these results indicate that zebrafish are more vulnerable to cadmium during the light in the dark phase. 3. The exposure of Gammarus chevreuxi by mercury-contaminated sediments showed a deleterious effect on the swimming activity even considered non-lethal concentrations. These effects were most pronounced during the light phase, which corresponds to the most active animal. 4. Our results suggest that the locomotor activity and the number of surfacings an early sign of the interaction of co-temperature stressors and contaminated sediments occur cone. The behavioral parameters studied in Gammarus. aequicauda and Gammarus. chevreuxi have a clear connection to the survival of organisms and can have an environmental relevance.